In addition to being the world leader in reproductive health, Serono has strong market positions in neurology, metabolism and growth. The Company's research programs are focused on growing these businesses and on establishing new therapeutic areas. Currently, there are seven products in development including six recombinant proteins. The Company operates in 45 countries, and its products are sold in over 100 countries. About 15 percent of couples of childbearing age seek medical help for infertility, usually after about two years of failing to conceive.
Anovulation is the most common cause of infertility in women.
Serono's vision is to develop innovative products to assist patients at every stage of the reproductive cycle, from ovulation to early pregnancy, to help them make their dream of a child come true.